Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Sutro Biopharma(STRO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for STRO
09/23/2026: STRO (1-star) is currently NOT-A-BUY. Pass it for now.
Sutro Biopharma is a clinical-stage biotechnology company that leverages its proprietary cell-free protein synthesis platform to develop antibody-drug conjugates (ADCs) for cancer treatment. Its main strengths include a highly efficient technology platform and strategic partnerships that provide external validation and non-dilutive funding. The company's investment story hinges on the success of its internal pipeline, specifically lead candidates like Luveltamab tazevibulin. Key risks include significant financial burn, binary clinical trial outcomes, and intense competition from much larger pharmaceutical firms. Sutro may suit risk-tolerant growth investors focused on clinical development, provided they monitor critical regulatory and trial data updates closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Sutro offers high growth potential linked to its technology platform, but with binary clinical trial risks. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts significantly to clinical news, making it a potential candidate during positive momentum cycles. |
| Value investor | Weak fit | The lack of earnings and reliance on speculative R&D pipelines makes it a poor fit for traditional value metrics. |
| Dividend investor | Weak fit | Sutro does not pay dividends and focuses all capital on development. |
| Low-risk investor | Weak fit | The high volatility and clinical risk profile are unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical data releases and sector sentiment. |
| Valuation risk | High | Valuation relies heavily on future projections rather than current cash flow. |
| Competition risk (Oncology/ADC) | High | Large pharma incumbents have more resources for large-scale clinical programs. |
| Business quality | Medium | The platform is technologically validated, but its commercial viability is not yet proven. |
| Dividend income | Low / none | Investors should not expect income from this equity. |
| Execution risk | High | Success depends on clinical and regulatory outcomes outside of the company's direct control. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 11.92% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 260.82M USD | Price to earnings Ratio - | 1Y Target Price 47.23 |
Price to earnings Ratio - | 1Y Target Price 47.23 | ||
Volume (30-day avg) 347.8K shares | Beta 1.49 | 52 Weeks Range 7.15 - 43.85 | Updated Date 09/23/2026 |
52 Weeks Range 7.15 - 43.85 | Updated Date 09/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -16.98 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Fees and milestone payments from partners utilizing the XpressCF platform. | This provides non-dilutive capital and validates the technology, though it is lumpy and unpredictable. |
| R&D Programs | Clinical and preclinical development of proprietary drug candidates. | This is the 'value engine' of the stock, representing the potential for future drug sales or assets. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 10.03 | Enterprise Value 113.23M | Price to Sales(TTM) 5.71 |
Enterprise Value 113.23M | Price to Sales(TTM) 5.71 | ||
Enterprise Value to Revenue 2.48 | Enterprise Value to EBITDA 41.71 | Shares Outstanding 16.58M | Shares Floating 10.77M |
Shares Outstanding 16.58M | Shares Floating 10.77M | ||
Percent Insiders 2.26 | Percent Institutions 98.76 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Sutro Biopharma
Exchange NASDAQ | Headquarters South San Francisco, CA, United States | ||
IPO Launch date 2018-09-27 | CEO & Director Ms. Jane Chung R.Ph. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.sutrobio.com |
Full time employees 128 | Website https://www.sutrobio.com | ||
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.